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Background: Lenalidomide (LND) is a new potent drug used for treatment of multiple myeloma. For its
pharmacokinetic studies and therapeutic monitoring, a proper analytical method was required.
Results: In this study, a non extractive and simple pre-column derivatization procedures have been proposed, for the
for trace determination of lenalidomide (LND) in human plasma by HPLC with fluorescence detection. Plasma samples
were treated with acetonitrile for protein precipitation then treated with copper acetate to form stable complexes with
the biogenic amines and mask their interference with the derivatization reaction of LND. Treated plasma samples
containing LND was derivatized with fluorescamine (FLC) in aqueous media at ambient temperature. Separation of the
derivatized LND was performed on Hypersil BDS C18 column (250 × 4.6 mm, 5 μm particle size) using a mobile phase
consisting of phosphate buffer (pH 4):methanol: tetrahydrofuran (70:10:20, v/v) at a flow rate of 1.0 mL/min. The
derivatized samples were monitored at an emission wavelength of 495 nm after excitation at a wavelength of 382 nm.
Under the optimum chromatographic conditions, a linear relationship with good correlation coefficient (r = 0.9997, n = 9)
was found between the peak area and LND concentrations in the range of 2–100 ng/mL. The limits of detection and
quantitation were 0.8 and 2.30 ng/mL, respectively. The intra- and inter-assay precisions were satisfactory and the
accuracy of the method was proved. The recovery of LND from the spiked human plasma was 99.30 ± 2.88.
Conclusions: The proposed method had high throughput as the analysis involved simple sample pre-treatment
procedure and a relatively short run-time (< 15 min). The results demonstrated that the method would have a great
value when it is applied in the therapeutic monitoring and pharmacokinetic studies for LND.
Keywords: Lenalidomide, Fluorescamine, HPLC, Fluorescence detection, Therapeutic drug, Monitoring, Pharmacokinetic
studiesBackground
Multiple myeloma (MM) is a B-cell malignancy of the
plasma cell and represents the second most common
haematological malignancy (about 10%), with non-
Hodgkin’s lymphoma being the most common. It is
estimated that approximately 21,500 new cases of multiple
myeloma are diagnosed per annum with approximately
16,000 deaths from the disease annually within the
European Union [1]. Multiple myeloma is characterized* Correspondence: idarwish@ksu.edu.sa
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reproduction in any medium, provided the orby an asymptomatic or subclinical phase before diagnosis
(possibly for several years), a chronic phase lasting several
years and an aggressive terminal phase. Multiple myeloma
is primarily a disease of the elderly, with a median age at
diagnosis of 68 years [2]. The disease leads to progressive
morbidity and eventual mortality by lowering resistance to
infection and causing significant skeletal destruction (with
bone pain, pathological fractures, and hypercalcaemia,
anaemia, renal failure [3], and, less commonly, neuro-
logical complications and hyperviscosity. From the time of
diagnosis, the survival without treatment is between 6 to
12 months and extends to 3 years with chemotherapy.l Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with fewer than 5% surviving longer than 10 years. MM is
characterized with the production of a homogeneous im-
munoglobulin fraction, called myeloma protein, by the
malignant plasma cells [4]. The classical triad of symptoms
is plasmacytosis (> 30% of plasma cells in the bone mar-
row), myeloma protein either in the urine or blood, and
lytic bone lesions [4,5].
In the 1990s, thalidomide (ThalomidW, Celgene Corpor-
ation) was used empirically in treatment of MM based on
its antiangiogenic activity and clinical activity in refractory
or relapsed myeloma [6]. However, thalidomide has sig-
nificant and dose-limiting side effects such as sleepiness,
constipation, neuropathy and teratogenicity [7]. These
toxic effects promoted the search for more potent but less
toxic thalidomide derivatives [8]. Lenalidomide (LND) is a
potent novel thalidomide analog which demonstrated
remarkable clinical activity against myeloma cells [8-13],
via a multiple-pathways mechanism [7,8,14-19].
LND has a more improved side effects profile than its
parent compound thalidomide, nevertheless, it causes some
dose-dependent side effects such as thrombocytopenia,
venous thromboembolism, and myelosuppression [20,21].
These side effects can be managed by combination therapy
and/or careful dose adjustment [22,23]. Because LND is
primarily excreted via kidneys, patients with renal insuffi-
ciency or failure must be dose adjusted to prevent the ex-
acerbation of its myelosuppressive effects [10,18]. Because
of the structural relation of LND to thalidomide, a terato-
genic effect can not ruled out, thus effective contraception
must be used by female patients [24,25]. Furthermore, stud-
ies showed large inter-individual pharmacokinetic variabil-
ity with concentration–toxicity relationship [26]. For these
reasons, a risk management, monitoring blood counts, and
therapeutic drug monitoring are required to achieve
the highest therapeutic benefits of LND and prevent its
fatal complications [9,27,28]. Nevertheless, the therapeutic
profile of LND is anticipated to encourage the development
of new pharmaceutical preparations for LND. As a
consequence, there is an increasing demand for proper ana-
lytical technologies for determination of pharmacokinetic
parameters in bioequivalence studies for LND, as well as in
its therapeutic monitoring.
Extensive literature survey showed that there were
only two methods for the determination of LND
in plasma [29,30]. These two methods involved liquid
chromatography-coupled with mass spectrometric detec-
tors (LC-MS). These two methods offered adequate sen-
sitivities; however they employed the expensive mass
detectors that are not available in most laboratories,
and involved laborious liquid-liquid sample extraction
procedures that negatively affected the accuracy of the
results, and limit the throughput of the procedures in
screening of large number of specimens. Accordingly,the development of a new alternative analytical method
for the determination of LND in plasma with adequate
sensitivity, improved simplicity, lower cost, and higher
throughput is urgently needed.
Fluorescence-based HPLC has been used as a sensitive
and less costly alternative approach to LC-MS. For these
reasons, the present research proposal was directed to-
wards the development and validation of a new simple
and sensitive HPLC method with fluorescence detection
for the determination of LND in plasma samples. The
method involved a very simple non-extractive isolation
of LND from plasma samples using protein precipitation
with acetonitrile followed by masking biogenic amines
by treatment with copper acetate, and derivatization
with fluorescamine (FLC). The method was successfully
applied to determination of LND in spiked human
plasma samples.
Experimental
The experimental research that is reported in this manu-
script did not get any approval of ethics committee as
the research has not been carried out on humans or
animals.
Chemicals and materials
Lenalidomide (LND), Free Base (3-(4’ aminoisoindoline-
1’-one)-1-piperidine-2, 6-dione) was purchased from LC
Laboratories (Woburn, MA, USA), 165 New Boston
Street Woburn, MA 01801, USA) and used as received.
Fluorescamine was purchased from Sigma Chemical Co.
(St. Louis, MO, USA). Copper acetate AR was obtained
from BDH, Poole, UK. Human plasma samples were
collected from normal healthy volunteers at King Khaled
University Hospital (Riyadh, Saudi Arabia), and they
were kept frozen at −20°C until the time of analysis.
Acetonitrile, tetrahydrofuran and all the other solvents
were of HPLC grade (Merck, Darmstadt, Germany).
Water was Millipore filtered. All other materials were of
analytical grade.
Preparation of solutions
Lenalidomide (LND) standard solution
An accurately weighed amount of LND was quantitatively
transferred into a calibrated volumetric flask, dissolved in
methanol and completed to volume with the same solvent
to produce a stock solution of 1 mg/mL and kept in the
refrigerator. On the day of analysis, the stock solution was
further diluted stepwise with water to obtain a working
standard solution containing 1.0 μg/mL.
Fluorescamine solution
An accurately weighed amount (5 mg) of Fluorescamine
was transferred into a 10-mL volumetric flask, dissolved
in acetonitrile and completed to volume with the same
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solution was freshly prepared and kept at -20°C pro-
tected from light to be used within seven days.
Phosphate buffer solution
Weighed amounts of di-sodium hydrogen orthophos-
phate (5.04 g) and potassium di-hydrogen orthophos-
phate (3.01 g) were dissolved in about 700 mL distilled
water. The pH of the solution was adjusted to 4.0±0.1
with glacial acetic acid using a calibrated pH-meter
(Microprocessor pH meter BT-500, Boeco, Germany).
Chromatographic system
HPLC apparatus consisted of a Shimadzu system
(Shimadzu Corporation, Kyoto, Japan) equipped with
two solvent delivery systems (LC-20 AD VP) with FCV-
12AH high pressure flow channel changeover valve, SIL-
20A auto-sampler, CTO-10A column oven, SPD-10A
UV-visible detector,, RF-10A XL fluorescence detector,
and SCL-10A vp system controller. The chromato-
graphic separations were performed on an analytical col-
umn Hypersil BDS C18 (250 mm length × 4.6 mm i.d.,
5 μm particle diameter) manufactured by Hypersil,
ThermoQuest Corporation (England). The column
temperature was kept constant at 25 ± 2°C. Separations
were performed in isocratic mode. The mobile phase
used for separation consisted of phosphate buffer
(pH 4): methanol: tetrahydrofuran (70: 10: 20, v/v)
pumped at flow rate of 1.0 mL/min. The mobile phase
was filtered by a Millipore vacuum filtration system
equipped with a 0.45 μm pore size filter, degassed by
ultrasonication, and further by bubbling with helium
gas. The samples (50 μL each) were injected by the aid
of the auto-sampler. The fluorescence detector was set
at 382 nm as an excitation wavelength and 495 nm as an
emission wavelength. The system control and data
acquisition were performed by Shimadzu CLASS-VP
software, version 5.032 (Shimadzu Corporation, Kyoto,
Japan). The relation between the area of LND peak and
its concentration was used as the basis for the quantifi-
cation. Alternatively, the regression equation was
derived.
General procedure and construction of the calibration curve
Accurately measured aliquots of LND working stock so-
lution (1.0 μg/mL) ranging from 20–400 μL were trans-
ferred into eight separate reaction vials each containing
500 μl plasma and 100 μl of a 0.2% solution of copper
acetate. The volumes in all vials were adjusted, as neces-
sary, to 1.0 mL with water. The vials were heated in a
boiling water-bath for 15 min. and cooled. 1.0 mL of
acetonitrile was added to each vial and centrifuged for
10 min at 10000 rpm. Portions of 500 μL of the super-
natant solutions were transferred into each of a set ofeight vials followed by 300 μL of water. 200 μL of FLC
solution (0.05% w/v) was added to all vials. This resulted
in a series of LND standard solutions covering the
working range of 5–100 ng/mL in the final reaction mix-
ture. The reaction in each vial was allowed to proceed at
room temperature for 5 min. before injecting 50 μL into
the HPLC system. Peak area values of the reaction prod-
uct between LND and FLC obtained at retention time of
around 11.6 min. were plotted versus the LND concen-
tration. A reagent blank treated in the same manner but
using water instead of the LND working stock solution
was prepared. Also another blank was prepared omitting
the addition of copper acetate.
Results and discussion
Design and strategy for assay development
LND contains a weakly absorbing chromphore in its mol-
ecule. This weak absorptivity does not facilitate the
adequate sensitivity for determination of LND levels in
plasma without pre-concentration of the samples, particu-
larly at the initial and elimination pharmacokinetic phases.
On the other hand, LND has no native fluorescence
and therefore a pre-colmn derivatization procedure was
necessary. Fluorescamine (40-phenylspiro[2-benzofuran-
3,20-furan]-1,30-dione) is a fluorogenic reagent which reacts
almost instantaneously with a wide variety of nucleophiles
including primary amines, even at very low concentrations,
forming fluorescent pyrrolinone moieties. The reaction is
almost instantaneous at room temperature in aqueous
media. The products are highly fluorescent, whereas the
reagent and its degradation products are nonfluorescent
[31]. Fluorescamine does not react with secondary amines
and forms a non-fluorescent adduct upon binding to
free NH3. LND contains a primary aromatic amino group
which makes it a good candidate readily reacting with
fluorescamine giving a highly fluorescent adduct.
Optimization of reaction variables
From our previous study of the reaction between LND
and FLC [32], we found that the reaction was dependent
on FLC concentration, pH of the reaction medium, the
nature of the diluting solvent and the duration of the re-
action time. The investigations revealed that the best
conditions for the reaction were found by maintaining a
final concentration of 0.0025% w/v of FLC, a neutral pH
using simple water as diluting solvent and leaving the re-
action to proceed for five minutes at room temperature.
Regarding the stoichiometry of the reaction and by ana-
logy to our study mentioned above, the reaction is
proposed to proceed as shown in Figure 1.
The excitation and emission spectra of the LND-FLC
derivative formed under the optimized conditions
were investigated using RF-5301 PC spectrofluorimeter
(Shimadzu, Kyoto, Japan). The reaction product was found
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sity at λex of 382 nm and λem of 495 nm. The present
study was devoted to adopt the above reaction in the
developing a sensitive HPLC method with fluorescence
detection for determination of LND in plasma.
Method development
Plasma is highly rich in nitrogen containing compounds
such as amino acids. Consequently, interference from
such endogenous amino acids is obviously expected. In
our present study, this interference was eliminated
through a selective complex formation between those α-
amino acids and copper ions furnished by addition of
copper acetate [33], a modification from the method
which describes the use copper hydroxide as the source
of copper ions [34]. Copper acetate did not interfere
with the determination of LND based on the following
facts: (1) copper forms a stable complex with α-amino
acids via binding of two amino acids by an amino
nityrogen and a carboxylic oxygen (i.e. NNOO coordin-
ation bonding); (2) The presence of carboxylic group in
α position to the primary amino group is essential for
the formation of the complex; (3) LND contains a
primary amino group however it does contain the
carboxylic oxygen to form the copper complex. For
these reasons, copper acetate did not interfere with the
determination of LND in the method described herein.
Acetonitrile is added to precipitate the large molecule
plasma proteins which are then separated by centrifuga-




















( ex = 381 nm; em = 494 nm)
Figure 1 Scheme for the reaction pathway between LND
and FLC.amino acid-copper complexes. The supernatant layers
which contain the LND were transferred into the set of
vials ready for the derivatization procedure as explained
above.
Method validation
Selectivity, linearity, limit of detection and limit of
quantitation
The selectivity of the method was evaluated by carrying
out blank experiments in the mobile phase to identify
the reagent peaks and the peaks due to the derivatized
plasma components. Typical chromatograms obtained
from FLC-derivatized blank plasma before and after
treatment with copper acetate are given in Figure 2A
and Figure 2B, respectively. The chromatogram of the
derivatization product between LND-spiked plasmaFigure 2 Chromatogram obtained from FLC-derivatized blank
plasma before treatment with copper acetate (A), after
treatment with copper acetate (B), derivatization product of
LND-spiked plasma (50 ng mL−1) pretreated with copper
acetate (C). The peak of retention time 11.6 min corresponds to
LND-FLC fluorescent product.
Table 1 Chromatographic parameters and performance
data of the proposed HPLC method for determination of
LND in plasma
Parameter Value
Retention time for LND-FLC complex (min) 11.6
Retention time of the nearest adjacent peak (min) 9.1
Capacity factor (K’) for LND-FLC complex 8.4
Resolution between LND-FLC complex and the
adjacent peak
3.5
LND-FLC complex peak asymmetry factor at 10%
peak height
1.33
Number of theoretical plates (N) per meter 13764
Height equivalent to theoretical plate (μm) 72.6
Correlation coefficient 0.9995
Slope (b) ± SD 3.11 × 105 ± 5.89 ×
103
Intercept (a) ± SD 1.272009× 105 ±
7.7 × 104
Linearity range (ng/mL) 5 – 100
LOD (ng/mL) 0.8
LOQ (ng/mL) 2.3
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reagent is given in Figure 2C. The effect of treatment
of the plasma with copper acetate before derivatization
with FLC is clearly observed in from the chromatograms.
The chromatogram given in Figure 2A shows how
great is the interference from the endogenous amines if the
plasma is not treated with copper acetate before
derivatization procedure. Very high intensity peaks cover
almost the whole range including the area where the
derivatized LND peak appears (~ 11.6 min). On the other
hand, the chromatogram of the plank plasma derivatized
with FLC after pretreatment with copper acetate (Figure 2B)
is absolutely free from any interference around the reten-













Mean ± S.D. 100.85 ± 2
a : Average of three replicates.
b : Average of four replicates.
* : %RSD not exceeding 2%.importance of treating the plasma samples with copper
acetate before derivatization with FLC.
The Chromatographic parameters and performance data
of the proposed HPLC method for determination of LND
in plasma are presented in Table 1. Under the optimized
conditions, a linear relationship with good correlation coef-
ficient (r = 0.9993 ± 0.00027, n = 6) was found between the
peak area of LND-FLC complex (Y) versus LND concentra-
tion (X) in the range of 5–100 ng/mL. The experiments
were performed using eight-point standard series. The
mean regression equation of the calibration curve obtained
was Y = 1.27 × 105 + 3.11 × 105 X. The % RSD value for the
slopes of the calibration curves was 1.89% (n = 6). The limit
of detection (LOD) and limit of quantitation (LOQ) were
calculated according to the ICH guidelines for validation of
analytical procedure based on the standard deviation of the
response and the slope of the calibration curve [35] using
the formula: LOD or LOQ = κσ/S, where κ = 3.3 for LOD
and 10 for LOQ, σ is the standard deviation of the re-
sponse, and S is the slope of the calibration curve.
Calculations on 6 replicate experimental injections, the
LOD and LOQ were 0.8 and 2.3 ng/mL respectively, and
the relative standard deviations (RSD) did not exceed 2%.
The LOD achieved in this method was lower than that
achieved in our previous method involving the same
derivatization procedure [32]. This is attributed due to the
difference in the detection systems between the conven-
tional fluorimeter (in the previous study) and the fluores-
cence HPLC detector in the method described herein.
Accuracy and precision
The accuracy and precision of the proposed method was
determined by intra-day and inter-day replicate analysis of
plasma spiked with different concentrations of LND
covering the working linear range. The inter-day assays
were carried out on five different days at the same concen-
tration levels for spiked plasma samples. The recoveryr determination of LND in spiked human plasma
Inter-assay b
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a mean value of 100.85 ± 2.07 whereas the values for the
inter-day analysis were 97.85 – 104.60 with a mean value of
100.91 ± 1.87 (Table 2), indicating the accuracy and preci-
sion of the proposed method.
Robustness and ruggedness
The robustness of the method was evaluated by making
minor changes on the parameters affecting the reaction
between the analyte and the reagent in addition to the
chromatographic parameters. In order to measure the
extent, the most critical parameters were interchanged
while keeping the other parameters unchanged. The chro-
matographic parameters were interchanged within the
range of 1-10% of the optimum recommended conditions.
The parameters involved were: the pH of the phosphate
buffer used in the mobile phase, the ratio between the
components of the mobile phase, pH of the derivatization
reaction mixture, and column temperature. The chroma-
tographic profile including: capacity factor (k’), retention
time (Rt), peak asymmetry, resolution and column
efficiency were calculated and compared with those of
the system suitability (Table 1). The results revealed that
the method was robust for these small changes in the
parameters. However, increasing the pH value above 7.3
resulted in marked decrease in the detector signal. The
increase in the column temperature generally decreases
the k’ values, and the column temperature has to be
maintained at 25±2°C.
The ruggedness of the method was evaluated by apply-
ing the recommended analytical procedures on the same
HPLC system on different days on the analysis of series
of LND-spiked plasma samples. The values of the cap-
acity factor (k’), retention time (Rt) and peak areas
obtained each time were not significant.
Conclusions
A simple, accurate and precise HPLC method with fluor-
escence detector for trace determination of LND after
its pre-column derivatization with FLC has been suc-
cessfully developed and validated. The sample prepar-
ation procedure was very simple and robust as it did not
involve any liquid-liquid extraction of the sample. It
was based on selective complexation of the endogenous
α- amino acids with copper ions and precipitation of the
proteins with acetonitrile before the derivatization reac-
tion. The derivatized sample was directly injected into
the HPLC system. The chromatographic separation was
based on a reversed phase mechanism carried out under
isocratic elution mode for only less than 15-min total
run time. The analytical results demonstrated that the
proposed method is suitable for the accurate quantifica-
tion of LND in human plasma at concentrations as low
as 2.3 ng/mL, with a wide linear range. The simpleprocedure involved in the sample preparation and the
short run-time added the property of a higher through-
put to the method. It is valuable for the combined
pharmacokinetic and bioavailability studies of LND in
human subjects.
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